A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
NCT ID: NCT02045862
Last Updated: 2024-10-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1829 participants
INTERVENTIONAL
2014-03-17
2016-09-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
NCT01972841
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
NCT01340027
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
NCT01908829
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
NCT01638000
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
NCT00501267
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mirabegron 50 mg
Participants received mirabegron 50 mg once a day for 52 weeks.
Mirabegron
Participants received mirabegron 50 mg orally once a day at the same time each day.
Placebo to match solifenacin
Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
Solifenacin 5 mg
Participants received solifenacin 5 mg once a day for 52 weeks.
Solifenacin succinate
Participants received solifenacin 5 mg orally once a day at the same time each day.
Placebo to match mirabegron
Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
Solifenacin 5 mg + Mirabegron 50 mg
Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.
Solifenacin succinate
Participants received solifenacin 5 mg orally once a day at the same time each day.
Mirabegron
Participants received mirabegron 50 mg orally once a day at the same time each day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Solifenacin succinate
Participants received solifenacin 5 mg orally once a day at the same time each day.
Mirabegron
Participants received mirabegron 50 mg orally once a day at the same time each day.
Placebo to match solifenacin
Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
Placebo to match mirabegron
Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject had completed study 178-CL-101 or study 905-EC-012 (This inclusion criterion would no longer apply once the recruitment for study 178-CL-101 and study 905-EC-012 had been completed. In that case the subject had to have symptoms of "wet" OAB (urinary frequency and urgency with incontinence) for at least 3 months);
* Subject was willing and able to complete the micturition diary and questionnaires correctly and able to measure his/her vital signs at home at stipulated time points, using the device provided by the study personnel, and to adequately record the readings;
Main Inclusion at Randomization (Visit 2):
* Subject had a micturition frequency of on average ≥ 8 times per 24-hour period during the last 7 days of the micturition diary period (incontinence episode should not be counted as a micturition).
* Subject had experienced at least 3 incontinence episodes during the last 7 days of the micturition diary period.
* Subject had experienced on average at least 1 urgency episode (grade 3 or 4 on Patient Perception of Intensity of Urgency Scale \[PPIUS\]) per 24-hour period during the 7-day micturition diary period.
Exclusion Criteria
* Subject had clinically significant bladder outflow obstruction at risk of urinary retention;
* Subject had significant PVR volume (\> 150 mL);
* Subject had significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor;
* Subject has an indwelling catheter or practices intermittent self-catheterization;
* Subject had evidence of a UTI (urine culture containing \> 100,000 cfu/mL), chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs;
* Subject had intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin;
Main Exclusion at Randomization (Visit 2):
* Subject had evidence of a urinary tract infection (UTI) (urine culture containing \> 100,000 cfu/mL) as assessed in the Screening visit (V1) samples. The subject could be rescreened after successful treatment of the UTI (confirmed by a dipstick negative for nitrite).
* Subject had an average total daily urine volume \> 3000 mL as recorded in the micturition diary period.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Europe B.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site US10049
Mobile, Alabama, United States
Site US10112
Mobile, Alabama, United States
Site US10104
Chandler, Arizona, United States
Site US10021
Phoenix, Arizona, United States
Site US10122
Anaheim, California, United States
Site US10082
Hawaiian Gardens, California, United States
Site US10132
Los Angeles, California, United States
Site US10133
Los Angeles, California, United States
Site US10149
Paramount, California, United States
Site US10003
San Diego, California, United States
Site US10106
Tarzana, California, United States
Site US10595
Valley Village, California, United States
Site US10053
Wheat Ridge, Colorado, United States
Site US10060
Bradenton, Florida, United States
Site US10097
Hialeah, Florida, United States
Site US10148
Hialeah, Florida, United States
Site US10153
Hialeah, Florida, United States
Site US10091
Jupiter, Florida, United States
Site US10150
New Port Richey, Florida, United States
Site US10124
Orlando, Florida, United States
Site US10134
Orlando, Florida, United States
Site US10009
Pembroke Pines, Florida, United States
Site US10554
Plantation, Florida, United States
Site US10037
Alpharetta, Georgia, United States
Site US10127
Roswell, Georgia, United States
Site US10120
Sandy Springs, Georgia, United States
Site US10078
Wichita, Kansas, United States
Site US10088
Lake Charles, Louisiana, United States
Site US10025
Shreveport, Louisiana, United States
Site US10558
Hanover, Maryland, United States
Site US10282
Boston, Massachusetts, United States
Site US10114
Watertown, Massachusetts, United States
Site US10110
Billings, Montana, United States
Site US10154
Missoula, Montana, United States
Site US10553
Lincoln, Nebraska, United States
Site US10002
Englewood, New Jersey, United States
Site US10047
Lawrenceville, New Jersey, United States
Site US10011
Albuquerque, New Mexico, United States
Site US10015
Albuquerque, New Mexico, United States
Site US10026
Garden City, New York, United States
Site US10040
Kingston, New York, United States
Site US10168
New York, New York, United States
Site US10126
Newburgh, New York, United States
Site US10028
Poughkeepsie, New York, United States
Site US10076
Concord, North Carolina, United States
Site US10129
Raleigh, North Carolina, United States
Site US10062
Winston-Salem, North Carolina, United States
Site US10050
Cleveland, Ohio, United States
Site US10067
Wadsworth, Ohio, United States
Site US10109
Oklahoma City, Oklahoma, United States
Site US10541
Medford, Oregon, United States
Site US10008
Bala-Cynwyd, Pennsylvania, United States
Site US10017
Philadelphia, Pennsylvania, United States
Site US10167
Pittsburgh, Pennsylvania, United States
Site US10250
Pittsburgh, Pennsylvania, United States
Site US10248
Pittsburgh, Pennsylvania, United States
Site US10063
Uniontown, Pennsylvania, United States
Site US10012
West Reading, Pennsylvania, United States
Site US10166
Charleston, South Carolina, United States
Site US10079
Mt. Pleasant, South Carolina, United States
Site US10023
Simpsonville, South Carolina, United States
Site US10101
Summerville, South Carolina, United States
Site US10006
Kingsport, Tennessee, United States
Site US10065
Corpus Christi, Texas, United States
Site US10085
Houston, Texas, United States
Site US10219
Houston, Texas, United States
Site US10093
Houston, Texas, United States
Site US10090
Hurst, Texas, United States
Site US10105
San Antonio, Texas, United States
Site US10111
San Antonio, Texas, United States
Site US10083
Virginia Beach, Virginia, United States
Site US10013
Burien, Washington, United States
Site US10004
Mountlake Terrace, Washington, United States
Site US10155
Seattle, Washington, United States
Site US10135
Walla Walla, Washington, United States
Site AU61005
Broadmeadow, New South Wales, Australia
Site AU61007
Randwick, New South Wales, Australia
Site AU61021
Randwick, New South Wales, Australia
Site AU61011
Wollongong, New South Wales, Australia
Site AU61022
Brisbane, Queensland, Australia
Site AU61010
Nambour, Queensland, Australia
Site AU61019
Sherwood, Queensland, Australia
Site AU61015
Daw Park, South Australia, Australia
Site AU61025
Footscray, Victoria, Australia
Site AU61002
Parkville, Victoria, Australia
Site AU61004
Perth, Western Australia, Australia
Site BE32004
Ghent, , Belgium
Site BE32014
Roeselare, , Belgium
Site BE32012
Sint-Truiden, , Belgium
Site BG35908
Plovdiv, , Bulgaria
Site BG35902
Rousse, , Bulgaria
Site BG35905
Sofia, , Bulgaria
Site BG35903
Sofia, , Bulgaria
Site CA15035
Edmonton, Alberta, Canada
Site CA15033
Vancouver, British Columbia, Canada
Site CA15008
Saint John, New Brunswick, Canada
Site CA15001
Barrie, Ontario, Canada
Site CA15006
Brampton, Ontario, Canada
Site CA15003
Brantford, Ontario, Canada
Site CA15007
Kitchener, Ontario, Canada
Site CA15013
Toronto, Ontario, Canada
Site CA15004
Toronto, Ontario, Canada
Site CA15026
Drummondville, Quebec, Canada
Site CA15039
Lévis, Quebec, Canada
Site CA15020
Montreal, Quebec, Canada
Site CA15025
Québec, Quebec, Canada
Site CA15027
Sherbrooke, Quebec, Canada
Site CA15040
Montreal, , Canada
Site CZ42015
Brno, , Czechia
Site CZ42003
Hradec Králové, , Czechia
Site CZ42001
Hradec Králové, , Czechia
Site CZ42010
Olomouc, , Czechia
Site CZ42014
Ostrava, , Czechia
Site CZ42005
Pilsen, , Czechia
Site CZ42008
Prague, , Czechia
Site CZ42007
Prague, , Czechia
Site CZ42013
Sternberk, , Czechia
Site CZ42009
Uherské Hradiště, , Czechia
Site CZ42006
Ústí nad Labem, , Czechia
Site DK45013
Aarhus, , Denmark
Site EE37201
Pärnu, , Estonia
Site FI35801
Kouvola, , Finland
Site DE49034
Munich, Bavaria, Germany
Site DE49032
Duisburg, North Rhine-Westphalia, Germany
Site DE49031
Bergisch Gladbach, Northwest, Germany
Site DE49013
Leipzig, Saxony, Germany
Site DE49003
Eisleben Lutherstadt, Saxony-Anhalt, Germany
Site DE49008
Bad Ems, , Germany
Site DE49002
Duisburg, , Germany
Site DE49010
Ganderkesee, , Germany
Site DE49011
Halle, , Germany
Site DE49001
Neustadt in Sachsen, , Germany
Site DE49026
Rostock, , Germany
Site DE49014
Sangerhausen, , Germany
Site HU36007
Kecskemét, Bacs-Kiskun Megye, Hungary
Site HU36005
Pécs, Baranya, Hungary
Site HU36003
Csongrád, Csongrád megye, Hungary
Site HU36001
Szentes, Csongrád megye, Hungary
Site HU36013
Sopron, Győr-Moson-Sopron, Hungary
Site HU36012
Veszprém, Veszprém megye, Hungary
Site IT39022
Ancona, , Italy
Site IT39007
Avellino, , Italy
Site IT39001
Latina, , Italy
Site IT39020
Milan, , Italy
Site LV37102
Liepāja, , Latvia
Site LV37103
Olaine, , Latvia
Site LV37105
Riga, , Latvia
Site LT37008
Kaunas, , Lithuania
Site LT37004
Kaunas, , Lithuania
Site LT37011
Kaunas, , Lithuania
Site LT37012
Klaipėda, , Lithuania
Site LT37010
Vilnius, , Lithuania
Site LT37003
Vilnius, , Lithuania
Site LT37007
Vilnius, , Lithuania
Site LT37009
Vilnius, , Lithuania
Site MY60002
Petaling Jaya, , Malaysia
Site MX52003
Mexico City, Mexico City, Mexico
Site NL31006
Enschede, NL, Netherlands
Site NL31002
Amsterdam, , Netherlands
Site NL31005
Nijmegen, , Netherlands
Site NL31010
Sneek, , Netherlands
Site NZ64001
Christchurch, Canterbury, New Zealand
Site NZ64002
Nelson, , New Zealand
Site NZ64003
Tauranga, , New Zealand
Site NZ64006
Whangarei, , New Zealand
Site NO47007
Ålesund, , Norway
Site NO47006
Hamar, , Norway
Site NO47008
Lierskogen, , Norway
Site PL48018
Bialystok, , Poland
Site PL48013
Chorzów, , Poland
Site PL48014
Gdynia, , Poland
Site PL48004
Lodz, , Poland
Site PL48010
Lublin, , Poland
Site PL48011
Mysłowice, , Poland
Site PL48016
Opole, , Poland
Site PL48005
Piaseczno, , Poland
Site PL48012
Warsaw, , Poland
Site PL48003
Warsaw, , Poland
Site PL48001
Warsaw, , Poland
Site PL48019
Wroclaw, , Poland
Site RO40014
Cluj-Napoca, Cluj, Romania
Site RO40004
Bucharest, , Romania
Site RO40001
Bucharest, , Romania
Site RO40005
Bucharest, , Romania
Site RO40010
Sibiu, , Romania
Site RO40002
Timișoara, , Romania
Site RU70015
Kazan', , Russia
Site RU70023
Penza, , Russia
Site RU70019
Saint Petersburg, , Russia
Site RU70002
Saint Petersburg, , Russia
Site RU70022
Saint Petersburg, , Russia
Site RU70014
Saint Petersburg, , Russia
Site RU70018
Ufa, , Russia
Site SG65002
Singapore, , Singapore
Site SG65003
Singapore, , Singapore
Site SK42105
Bratislava, , Slovakia
Site SK42107
Košice, , Slovakia
Site SK42101
Košice, , Slovakia
Site SK42103
Nitra, , Slovakia
Site SK42108
Poprad, , Slovakia
Site SK42104
Prešov, , Slovakia
Site SK42102
Trenčín, , Slovakia
Site SK42106
Trenčín, , Slovakia
Site SI38604
Murska Sobota, , Slovenia
Site ZA27001
Centurion, Gauteng, South Africa
Site ZA27002
Roodepoort, Gauteng, South Africa
Site ZA27006
Durban, KwaZulu-Natal, South Africa
Site ZA27013
Meyerspark, Pretoria, South Africa
Site ZA27007
Paarl, Western Cape, South Africa
Site KR82004
Suwon, Gyeonggi-do, South Korea
Site KR82014
Bucheon-si, Gyunggido, South Korea
Site KR82012
Seoul, Gyunggido, South Korea
Site KR82010
Jeonju, Jeollabuk-do South Korea, South Korea
Site KR82006
Busan, , South Korea
Site KR82016
Busan, , South Korea
Site KR82005
Daegu, , South Korea
Site KR82029
Daegu, , South Korea
Site KR82019
Daejeon, , South Korea
Site KR82023
Incheon, , South Korea
Site KR82003
Seoul, , South Korea
Site KR82021
Seoul, , South Korea
Site KR82020
Seoul, , South Korea
Site KR82030
Seoul, , South Korea
Site KR82013
Seoul, , South Korea
Site KR82017
Seoul, , South Korea
Site KR82002
Seoul, , South Korea
Site KR82008
Seoul, , South Korea
Site KR82015
Seoul, , South Korea
Site KR82001
Seoul, , South Korea
Site ES34004
Madrid, , Spain
Site ES34015
Madrid, , Spain
Site ES34009
Madrid, , Spain
Site ES34002
Valencia, , Spain
Site SE46007
Borås, , Sweden
Site SE46005
Malmo, , Sweden
Site SE46016
Stockholm, , Sweden
Site SE46012
Stockholm, , Sweden
Site SE46003
Stockholm, , Sweden
Site SE46009
Uppsala, , Sweden
Site TH66008
Bangkok, , Thailand
Site TH66009
Khon Kaen, , Thailand
Site UA38002
Cherenigiv, , Ukraine
Site UA38015
Chernivtsi, , Ukraine
Site UA38013
Dnipro, , Ukraine
Site UA38007
Kiev, , Ukraine
Site UA38003
Kyiv, , Ukraine
Site UA38010
Kyiv, , Ukraine
Site UA38008
Zaporizhzhya, , Ukraine
Site GB44001
Sheffield, South Yorkshire, United Kingdom
Site GB44006
Plymouth, , United Kingdom
Site GB44009
Watford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol. 2018 Oct;74(4):501-509. doi: 10.1016/j.eururo.2018.05.005. Epub 2018 Jun 1.
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on the Astellas Clinical Study Results website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-005736-29
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
178-CL-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.